Regulatory Prototype for Biological Products in the United States
Journal of Pharmaceutical Research International · pp. 60–72 · Published 10 May 2021
10.9734/jpri/2021/v33i28B31539Abstract
Biological products are used for the treatment of many disease, so the biological application submitted for the approval of products are also increasing. The progress of a biosimilarproduct is more difficult and expensive than a small molecule generic product. Biosimilars are not true generic drugs, but demonstrate a high degree of similarity to the reference biological product. In order to improve access to costly biological treatments, a biosimilar pathway in the US was established under the Biologics Price Competition and Innovation Act of 2009. The study highlighted the “Regulatory prospective for the registration of Biological products in US” and a brief description about the development, Manufacturing and approval process of biosimilar products. This article is also focused on the regulatory framework, Biological License Application, Purple book, and Pharmacovigilance of biological products.
Cited by 0
No indexed citations yet.
Related research
- Development or Adaptation of Clinical Guidelines in the Health System of Developing Countries: A Review Article — shares topic coverage
- Development of Pumpkin Pudding-like Food Using Soybeans [Glycine max (L.) Merr.] — shares topic coverage
- Development of a High Value Nutritious Baking Flour from Dried Ripe Banana Peels — shares topic coverage
- A Renewed Understanding of Shell-shape Diversity among Marine Gastropod Species: Invariance and Covariance between Geometrical Parameters in Conispirally Coiled Shells — shares topic coverage
- Growth and Development of Groundnut (Arachis hypogaea L.) as Influenced by Different Levels and Timing of Phosphogypsum Nutrition — shares topic coverage
Article metrics
Real usage data collected on this platform.
11
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.